Grace Therapeutics (GRCE) Receivables (2017 - 2024)

Grace Therapeutics has disclosed Receivables across 8 years of filings, most recently posting $418000.0 for Q2 2024.

• In Q2 2024, Receivables fell 52.87% year-over-year to $418000.0; the TTM figure through Jun 2024 stood at $418000.0 (down 52.87% YoY), while the FY2024 annual figure was $1.4 million, up 69.09% from the prior year.
• Receivables came in at $418000.0 for Q2 2024 at Grace Therapeutics, down from $1.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.4 million in Q1 2024 to a low of $238000.0 in Q4 2021.
• Average Receivables over 5 years is $731888.9, with a median of $701500.0 recorded in 2020.
• Year-over-year, Receivables sank 61.55% in 2021 and jumped 226.89% in 2022.
• Over 5 years, Receivables stood at $619000.0 in 2020, then slumped by 61.55% to $238000.0 in 2021, then jumped by 226.89% to $778000.0 in 2022, then surged by 44.34% to $1.1 million in 2023, then slumped by 62.78% to $418000.0 in 2024.
• Per Business Quant data, the three most recent Receivables figures were $418000.0 in Q2 2024, $1.4 million in Q1 2024, and $1.1 million in Q4 2023.